Marker Therapeutics (MRKR) Stock Price, Quote, News & History

Marker Therapeutics Inc (MRKR) Stock Price, Quote, News & History

MRKRNASDAQ

Trade with Public

$1.30

-0.05-3.70%

At close: Mar 27, 5:00 PM EST

$1.39

0.096.92%

After Hours: Mar 26, 5:59 AM EST

Key Statistics

Open

$1.34

$1.30

Volume / Avg.

89.84K / 305.31K

Day Range

$1.26 - $1.39

52 Wk Range

0.81 - 4.07

Market Cap

$23.18M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

4.43%

Days to Cover

4.65

Recent Marker Therapeutics Inc News

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Marker Therapeutics reports strong safety and efficacy data for MT-601 in lymphoma patients, with durable responses and no serious adverse events.

Vandana Singh

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.

Vandana Singh

Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?

Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-12.01M

Investing Cash Flow (TTM)

Financing Cash Flow (TTM)

9.86M

Free Cash Flow (TTM)

-12.01M

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-2.15M

Analyst Trends and Forecast

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.77M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

1.36

Earnings Yield % (TTM)

-57.66%

Earnings Yield % (FWD)

-61.31%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$1.01

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$16.07M

Debt to Equity

Issuance of Debt (TTM)

Repayment of Debt (TTM)

Key Statistics

Open

$1.34

$1.30

Volume / Avg.

89.84K / 305.31K

Day Range

$1.26 - $1.39

52 Wk Range

0.81 - 4.07

Market Cap

$23.18M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

4.43%

Days to Cover

4.65

About

Sector

Health Care

Industry

Biotechnology

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Marker Therapeutics (MRKR) stock?

You can purchase shares of Marker Therapeutics (NASDAQ:MRKR) through any online brokerage.

View our list of the best stock brokerages

Who are Marker Therapeutics (MRKR) competitors?

Other companies in Marker Therapeutics’s space includes: Outlook Therapeutics Inc (NASDAQ:OTLK), Skye Bioscience Inc (NASDAQ:SKYE), Curis Inc (NASDAQ:CRIS), Intensity Therapeutics Inc (NASDAQ:INTS) and Nanoviricides Inc (AMEX:NNVC).

What is the forecast, or price target, for Marker Therapeutics (MRKR) stock?

Marker Therapeutics has a consensus price target of $12.38.

What is the current price for Marker Therapeutics (MRKR)?

The stock price for Marker Therapeutics (NASDAQ: MRKR) is $1.39 last updated March 26, 2026 at 5:59 AM EDT.

Does Marker Therapeutics (MRKR) pay a dividend?

There are no upcoming dividends for Marker Therapeutics.

When is Marker Therapeutics (NASDAQ:MRKR) reporting earnings?

Marker Therapeutics does not have any upcoming earnings scheduled.

Is Marker Therapeutics (MRKR) going to split?

There is no upcoming split for Marker Therapeutics.

What sector and industry does Marker Therapeutics (MRKR) operate in?

Marker Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Outlook Therapeutics Inc

Intensity Therapeutics Inc

Barinthus Biotherapeutics PLC

NASDAQ:BRNS

$0.56

1.79%

Vistagen Therapeutics Inc

NASDAQ:VTGN

$0.56

-1.43%

Tevogen Bio Holdings Inc

NASDAQ:TVGN

$4.97

12.17%

Key Statistics

Open

$1.34

$1.30

Volume / Avg.

89.84K / 305.31K

Day Range

$1.26 - $1.39

52 Wk Range

0.81 - 4.07

Market Cap

$23.18M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

4.43%

Days to Cover

4.65

Recent Marker Therapeutics Inc News

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Marker Therapeutics reports strong safety and efficacy data for MT-601 in lymphoma patients, with durable responses and no serious adverse events.

Vandana Singh

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Vandana Singh

Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-12.01M

Investing Cash Flow (TTM)

Financing Cash Flow (TTM)

9.86M

Free Cash Flow (TTM)

-12.01M

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-2.15M

Analyst Trends and Forecast

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.77M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

1.36

Earnings Yield % (TTM)

-57.66%

Earnings Yield % (FWD)

-61.31%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$1.01

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$16.07M

Debt to Equity

Issuance of Debt (TTM)

Repayment of Debt (TTM)

Key Statistics

Open

$1.34

$1.30

Volume / Avg.

89.84K / 305.31K

Day Range

$1.26 - $1.39

52 Wk Range

0.81 - 4.07

Market Cap

$23.18M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

4.43%

Days to Cover

4.65

About

Sector

Health Care

Industry

Biotechnology

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry